688105 Nanjing Vazyme Biotech
- 18.45
- -0.63-3.30%
Nanjing Vazyme Biotech News
Novi Zan\'s announcement on adjusting the maximum share repurchase price after implementing the 2023 equity distribution
Novi Zang\'s progress announcement on the repurchase of the company\'s shares through centralized bidding transactions
Huatai United Securities Co., Ltd.\'s inspection opinion on the departure of core technical personnel of Nanjing Novizan Biotechnology Co., Ltd.
Novi Zan\'s announcement on the departure of core technical staff
Announcement of Resolutions of the 9th Meeting of the 2nd Board of Supervisors of Novizam
Resolutions of the first meeting of the 2nd Special Meeting of Independent Directors of the Board of Directors
Novi Zan\'s special report on the storage and actual use of funds raised for the 2024 semi-year
Semi-annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Focus on Return” Special Action Plan
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Novozymes Investor Relations Activity Record for August 2024.
Notice from Novartis on the voluntary disclosure of fully-owned subsidiary's acquisition of medical instruments registration certificate.
Announcement on the Progress of Novozymes's Share Repurchase by Centralized Bidding Trading Method.
Notice from Nouveau Health regarding the voluntary disclosure of its subsidiaries' products obtaining CE IVDR certification from the European Union.
Voluntary disclosure announcement of Noritz's 2024 interim performance forecast.
Announcement on the Progress of Novozymes's Share Repurchase by Centralized Bidding Trading Method.
Notice of Implementation of Annual Equity Distribution of Nuoweizan in 2023.
Announcement by Nouveau International on the adjustment of the total amount of cash dividends for profit distribution for 2023.
Notice of Resolutions of the 2023 Annual Shareholders' Meeting of NuoWeiZan
Legal Opinion of Tianyuan Law Firm regarding the 2023 Shareholders' Meeting of Nanjing Novozymes Biotechnology Co., Ltd. in Peking
Analysis
Price Target
No Data
